Heterodimer formation by Oct4 and Smad3 differentially regulates epithelial-to-mesenchymal transition-associated factors in breast cancer progression

Redig, 2013, Breast cancer as a systemic disease: a view of metastasis, J. Intern. Med., 274, 113, 10.1111/joim.12084 Torre, 2015, Global cancer statistics, 2012, CA Cancer J. Clin., 65, 87, 10.3322/caac.21262 Sen, 2002, Cancer patterns in eastern India: the first report of the Kolkata cancer registry, Int. J. Cancer, 100, 86, 10.1002/ijc.10446 Ottewell, 2015, Molecular alterations that drive breast cancer metastasis to bone, Bonekey Rep, 4, 643, 10.1038/bonekey.2015.10 Xu, 2009, TGF-β-induced epithelial to mesenchymal transition, Cell Res., 19, 156, 10.1038/cr.2009.5 Lamouille, 2014, Molecular mechanisms of epithelial–mesenchymal transition, Nat. Rev. Mol. Cell Biol., 15, 178, 10.1038/nrm3758 Barrallo-Gimeno, 2005, The snail genes as inducers of cell movement and survival: implications in development and cancer, Development, 132, 3151, 10.1242/dev.01907 Dhasarathy, 2011, The transcription factors snail and slug activate the transforming growth factor-Beta signaling pathway in breast cancer, PLoS One, 6, 10.1371/journal.pone.0026514 Pang, 2016, TGF-β1-induced EMT promotes targeted migration of breast cancer cells through the lymphatic system by the activation of CCR7/CCL21-mediated chemotaxis, Oncogene, 35, 748, 10.1038/onc.2015.133 Heldin, 2009, Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition, Curr. Opin. Cell Biol., 21, 166, 10.1016/j.ceb.2009.01.021 Massague, 2008, TGF beta in cancer, Cell, 134, 215, 10.1016/j.cell.2008.07.001 Papageorgis, 2015, TGF-β signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis, J. Oncol., 2015, 587193, 10.1155/2015/587193 Zarzynska, 2014, Two faces of TGF-Beta1 in breast cancer, Mediat. Inflamm., 2014, 141747, 10.1155/2014/141747 Geertz, 2010, Experimental strategies for studying transcription factor–DNA binding specificities, Brief. Funct. Genomics, 9, 362, 10.1093/bfgp/elq023 Luscombe, 2000, An overview of the structures of protein-DNA complexes, Genome Biol., 1, 10.1186/gb-2000-1-1-reviews001 Velasco-Velázquez, 2011, The role of breast cancer stem cells in metastasis and therapeutic implications, Am. J. Pathol., 179, 2, 10.1016/j.ajpath.2011.03.005 Geng, 2014, Breast cancer stem cells: multiple capacities in tumor metastasis, Cancer Lett., 349, 1, 10.1016/j.canlet.2014.03.036 Sheridan, 2006, CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis, Breast Cancer Res., 8, R59, 10.1186/bcr1610 Kim, 2011, OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer, Inst. Lab. Anim. Res. J., 27, 147, 10.5625/lar.2011.27.2.147 Boiani, 2005, Regulatory networks in embryo-derived pluripotent stem cells, Nat. Rev. Mol. Cell Biol., 6, 872, 10.1038/nrm1744 Pesce, 1998, Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation, Mech. Dev., 71, 89, 10.1016/S0925-4773(98)00002-1 Atlasi, 2008, OCT4 spliced variants are differentially expressed in human pluripotent and nonpluripotent cells, Stem Cells, 26, 3068, 10.1634/stemcells.2008-0530 Pesce, 2001, Oct-4: gatekeeper in the beginnings of mammalian development, Stem Cells, 19, 271, 10.1634/stemcells.19-4-271 Ling, 2012, Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines, Oncol. Lett., 4, 1264, 10.3892/ol.2012.916 Yin, 2015, Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/snail signaling, J. Hematol. Oncol., 8, 23, 10.1186/s13045-015-0119-3 Atlasi, 2007, OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer, Int. J. Cancer, 120, 1598, 10.1002/ijc.22508 Liu, 2015, OCT4 mediates FSH-induced epithelial-mesenchymal transition and invasion through the ERK1/2 signaling pathway in epithelial ovarian cancer, Biochem. Biophys. Res. Commun., 461, 525, 10.1016/j.bbrc.2015.04.061 Ezeh, 2005, Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma, Cancer, 104, 2255, 10.1002/cncr.21432 Kumar, 2012, Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation, Oncogene, 31, 4898, 10.1038/onc.2011.656 Wen, 2010, Oct4 and Nanog expression is associated with early stages of pancreatic carcinogenesis, Pancreas, 39, 622, 10.1097/MPA.0b013e3181c75f5e Meng, 2010, Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer, Cancer Biol. Ther., 9, 295, 10.4161/cbt.9.4.10666 Zeineddine, 2014, The Oct4 protein: more than a magic stemness marker, Am. J. Stem Cells, 3, 74 Koo, 2015, Oct4 is a critical regulator of stemness in head and neck squamous carcinoma cells, Oncogene, 34, 2317, 10.1038/onc.2014.174 Boumahdi, 2014, SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma, Nature, 511, 246, 10.1038/nature13305 Abubaker, 2014, Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden, BMC Cancer, 14, 317, 10.1186/1471-2407-14-317 Pucéat, 2007, TGF beta in the differentiation of embryonic stem cells, Cardiovasc. Res., 74, 256, 10.1016/j.cardiores.2006.12.012 Au, 2015, TGF-βI regulates cell migration through pluripotent transcription factor OCT4 in endometriosis, PLoS One, 10, 10.1371/journal.pone.0145256 Mullen, 2011, Master transcription factors determine cell-type-specific responses to TGF-β signaling, Cell, 147, 565, 10.1016/j.cell.2011.08.050 Hadjimichael, 2015, Common stemness regulators of embryonic and cancer stem cells, World J. Stem Cells, 7, 1150, 10.4252/wjsc.v7.i9.1150 Massagué, 2012, TGF-β control of stem cell differentiation genes, FEBS Lett., 586, 1953, 10.1016/j.febslet.2012.03.023 Chen, 2015, The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer, J. Transl. Med., 13, 168, 10.1186/s12967-015-0521-1 Jenh, 2001, Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor, Cytokine, 15, 113, 10.1006/cyto.2001.0923 Gunn, 1998, A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1, Nature, 391, 799, 10.1038/35876 Vissers, 2001, BLC (CXCL13) is expressed by different dendritic cell subsets in vitro and in vivo, Eur. J. Immunol., 31, 1544, 10.1002/1521-4141(200105)31:5<1544::AID-IMMU1544>3.0.CO;2-I Carlsen, 2004, Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis, Blood, 104, 3021, 10.1182/blood-2004-02-0701 Panse, 2008, Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients, Br. J. Cancer, 99, 930, 10.1038/sj.bjc.6604621 Havenar-Daughton, 2016, CXCL13 is a plasma biomarker of germinal center activity, Proc. Natl. Acad. Sci. U. S. A., 113, 2702, 10.1073/pnas.1520112113 Allen, 2004, Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5, Nat. Immunol., 5, 943, 10.1038/ni1100 Meijer, 2006, The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver, Cancer Res., 66, 9576, 10.1158/0008-5472.CAN-06-1507 Airoldi, 2008, CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow, Cancer Immunol. Immunother., 57, 541, 10.1007/s00262-007-0392-2 El Haibi, 2010, PI3Kp110-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells, Mol. Cancer, 9, 85, 10.1186/1476-4598-9-85 Biswas, 2014, CXCL13-CXCR5 co-expression regulates epithelial to mesenchymal transition of breast cancer cells during lymph node metastasis, Breast Cancer Res. Treat., 143, 265, 10.1007/s10549-013-2811-8 Manzo, 2008, Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint, Arthritis Rheum., 58, 3377, 10.1002/art.23966 Kobayashi, 2013, A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium, Arthritis Rheum., 65, 3063, 10.1002/art.38173 Kobayashi, 2016, TGF-β induces the differentiation of human CXCL13-producing CD4(+) T cells, Eur. J. Immunol., 46, 360, 10.1002/eji.201546043 Zeineddine, 2006, Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development, Dev. Cell, 11, 535, 10.1016/j.devcel.2006.07.013 Burdick, 2012, Expression of E-selectin ligands on circulating tumor cells: cross-regulation with cancer stem cell regulatory pathways?, Front. Oncol., 2, 103, 10.3389/fonc.2012.00103 Hu, 2011, Downregulation of transcription factor Oct4 induces an epithelial-to-mesenchymal transition via enhancement of Ca2+ influx in breast cancer cells, Biochem. Biophys. Res. Commun., 411, 786, 10.1016/j.bbrc.2011.07.025 Wang, 2015, The emerging roles of Oct4 in tumor-initiating cells, Am. J. Phys. Cell Physiol., 309, C709, 10.1152/ajpcell.00212.2015 Lu, 2011, Extracellular matrix degradation and remodeling in development and disease, Cold Spring Harb. Perspect. Biol., 3, a005058, 10.1101/cshperspect.a005058 Venning, 2015, Targeting ECM disrupts cancer progression, Front. Oncol., 5, 224, 10.3389/fonc.2015.00224 Kessenbrock, 2010, Matrix metalloproteinases: regulators of the tumor microenvironment, Cell, 141, 52, 10.1016/j.cell.2010.03.015 Duffy, 2000, Metalloproteinases: role in breast carcinogenesis, invasion and metastasis, Breast Cancer Res., 2, 252, 10.1186/bcr65 Mehlen, 2006, Metastasis: a question of life or death, Nat. Rev. Cancer, 6, 449, 10.1038/nrc1886 Pickup, 2013, The roles of TGFβ in the tumour microenvironment, Nat. Rev. Cancer, 13, 788, 10.1038/nrc3603 Gaarenstroom, 2014, TGF-β signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation, Semin. Cell Dev. Biol., 32, 107, 10.1016/j.semcdb.2014.01.009 Kaufhold, 2016, Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication, J. Exp. Clin. Cancer Res., 35, 84, 10.1186/s13046-016-0359-2 Lee, 2017, Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog), Tumour Biol., 39, 10.1177/1010428317692253 Wang, 2014, Oct-4 and Nanog promote the epithelial-mesenchymal transition of breast cancer stem cells and are associated with poor prognosis in breast cancer patients, Oncotarget, 5, 10803, 10.18632/oncotarget.2506 Moses, 2011, TGF-beta biology in mammary development and breast cancer, Cold Spring Harb. Perspect. Biol., 3, 10.1101/cshperspect.a003277 Barcellos-Hoff, 2009, Transforming growth factor-beta in breast cancer: too much, too late, Breast Cancer Res., 11, 202, 10.1186/bcr2224 Peinado, 2004, Transcriptional regulation of cadherins during development and carcinogenesis, Int. J. Dev. Biol., 48, 365, 10.1387/ijdb.041794hp Brierley, 2016 Bloom, 1957, (1957) histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years, Br. J. Cancer, 11, 359, 10.1038/bjc.1957.43